Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$4.31 +7.6%	$2.75	$1.14 ▼ $7.20	$257.55M	0.9	856,525 shs	757,113 shs
ARAV ARAVIVE	$0.04	$0.04	$0.04 ▼ $2.46	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$13.64 +0.1%	$12.47	$8.04 ▼ $25.88	$373.73M	2.27	421,186 shs	172,653 shs
CRVS Corvus Pharmaceuticals	$3.94 -1.1%	$3.84	$1.77 ▼ $10.00	$269.27M	0.58	830,254 shs	313,955 shs
HROW Harrow	$31.78 +4.0%	$28.32	$20.85 ▼ $59.23	$1.16B	0.41	495,276 shs	257,698 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+13.59%	+75.71%	+127.78%	+34.53%
ARAV ARAVIVE	0.00%	0.00%	0.00%	0.00%	0.00%
ARCT Arcturus Therapeutics	0.00%	+2.29%	+14.48%	+49.67%	-37.82%
CRVS Corvus Pharmaceuticals	0.00%	+1.16%	+0.64%	+38.07%	+121.07%
HROW Harrow	0.00%	+2.91%	+10.65%	+35.12%	+47.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.8073 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.8	0.6
ARAV ARAVIVE	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	3.7657 of 5 stars	4.6	2.0	0.0	0.0	3.2	2.5	0.6
CRVS Corvus Pharmaceuticals	2.4724 of 5 stars	3.5	1.0	0.0	0.0	1.6	3.3	0.6
HROW Harrow	2.6828 of 5 stars	3.5	2.0	0.0	0.0	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	120.67% Upside
ARAV ARAVIVE	0.00	N/A	N/A	N/A
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	296.04% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	281.19% Upside
HROW Harrow	3.00	Buy	$61.40	93.20% Upside

Current Analyst Ratings Breakdown

Latest ARCT, ALDX, CRVS, ARAV, and HROW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/12/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$62.00
6/10/2025	HROW Harrow	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/12/2025	HROW Harrow	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$57.00 ➝ $60.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
ARAV ARAVIVE	$9.14M	0.32	N/A	N/A	N/A	∞
ARCT Arcturus Therapeutics	$152.31M	2.43	N/A	N/A	$8.90 per share	1.53
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A
HROW Harrow	$199.61M	5.84	$0.14 per share	232.19	$1.95 per share	16.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.97	N/A	N/A	N/A	N/A	-72.58%	-52.32%	7/30/2025 (Estimated)
ARAV ARAVIVE	-$76.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$0.98	N/A	N/A	N/A	N/A	-24.04%	-13.90%	8/5/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.56	N/A	79.45	N/A	-10.19%	-25.01%	-4.27%	8/6/2025 (Estimated)

Latest ARCT, ALDX, CRVS, ARAV, and HROW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/8/2025	Q1 2025	HROW Harrow	$0.02	-$0.38	-$0.40	-$0.50	$57.00 million	$47.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
ARAV ARAVIVE	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	0.24	6.49	6.49
ARAV ARAVIVE	N/A	N/A	N/A
ARCT Arcturus Therapeutics	0.06	5.64	5.64
CRVS Corvus Pharmaceuticals	N/A	4.90	4.90
HROW Harrow	2.01	0.91	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
ARAV ARAVIVE	35.80%
ARCT Arcturus Therapeutics	94.54%
CRVS Corvus Pharmaceuticals	46.64%
HROW Harrow	72.76%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
ARAV ARAVIVE	60.40%
ARCT Arcturus Therapeutics	16.60%
CRVS Corvus Pharmaceuticals	28.50%
HROW Harrow	15.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	15	59.90 million	54.15 million	Optionable
ARAV ARAVIVE	20	73.56 million	29.13 million	No Data
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	48.74 million	Optionable
HROW Harrow	180	36.69 million	31.12 million	Optionable

ARCT, ALDX, CRVS, ARAV, and HROW Headlines

Recent News About These Companies

Are Options Traders Betting on a Big Move in Harrow Stock?

July 2, 2025 | msn.com

Harrow Earns Relative Strength Rating Upgrade

June 30, 2025 | msn.com

Harrow, Inc. (NASDAQ:HROW) Shares Bought by Westside Investment Management Inc.

June 30, 2025 | marketbeat.com

Stocks Generating Improved Relative Strength: Harrow

June 26, 2025 | msn.com

We Might See A Profit From Harrow, Inc. (NASDAQ:HROW) Soon

June 26, 2025 | finance.yahoo.com

Woodmont Investment Counsel LLC Buys 22,293 Shares of Harrow, Inc. (NASDAQ:HROW)

June 21, 2025 | marketbeat.com

Harrow Shows Market Leadership With Jump To 83 RS Rating

June 20, 2025 | msn.com

Assenagon Asset Management S.A. Sells 99,446 Shares of Harrow, Inc. (NASDAQ:HROW)

June 20, 2025 | marketbeat.com

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

June 19, 2025 | finance.yahoo.com

I Am Swimming In Dividends With +7% Yields

June 13, 2025 | seekingalpha.com

Harrow, Inc. (NASDAQ:HROW) Given Consensus Recommendation of "Buy" by Brokerages

June 12, 2025 | marketbeat.com

Harrow (NASDAQ:HROW) Now Covered by Analysts at BTIG Research

June 12, 2025 | marketbeat.com

What is William Blair's Estimate for Harrow Q2 Earnings?

June 12, 2025 | marketbeat.com

William Blair Initiates Coverage of Harrow (HROW) with Outperform Recommendation

June 12, 2025 | msn.com

Harrow wins new Outperform at William Blair after licensing deal for pain drug

June 10, 2025 | msn.com

Harrow (NASDAQ:HROW) Shares Gap Up - Still a Buy?

June 10, 2025 | marketbeat.com

Harrow (NASDAQ:HROW) Coverage Initiated at William Blair

June 10, 2025 | marketbeat.com

Harrow acquires U.S. commercial rights to BYQLOVI from Formosa Pharmaceuticals

June 10, 2025 | msn.com

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

June 9, 2025 | prnewswire.com

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

June 9, 2025 | businesswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 29,262 Shares of Harrow, Inc. (NASDAQ:HROW)

June 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, ALDX, CRVS, ARAV, and HROW Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$4.30 +0.31 (+7.63%)

Closing price 07/3/2025 03:50 PM Eastern

Extended Trading

$4.30 0.00 (0.00%)

As of 07/3/2025 04:58 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

ARAVIVE NASDAQ:ARAV

$0.04 0.00 (0.00%)

As of 07/3/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Arcturus Therapeutics NASDAQ:ARCT

$13.64 +0.02 (+0.11%)

As of 07/3/2025 03:11 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$3.94 -0.05 (-1.13%)

Closing price 07/3/2025 02:54 PM Eastern

Extended Trading

$3.96 +0.02 (+0.51%)

As of 07/3/2025 04:51 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Harrow NASDAQ:HROW

$31.78 +1.21 (+3.96%)

As of 07/3/2025 03:29 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time